These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21283635)

  • 1. Biophysical characterization of the olfactomedin domain of myocilin, an extracellular matrix protein implicated in inherited forms of glaucoma.
    Orwig SD; Lieberman RL
    PLoS One; 2011 Jan; 6(1):e16347. PubMed ID: 21283635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glaucoma-associated olfactomedin domain of myocilin is a novel calcium binding protein.
    Donegan RK; Hill SE; Turnage KC; Orwig SD; Lieberman RL
    J Biol Chem; 2012 Dec; 287(52):43370-7. PubMed ID: 23129764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder.
    Burns JN; Turnage KC; Walker CA; Lieberman RL
    Biochemistry; 2011 Jul; 50(26):5824-33. PubMed ID: 21612213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence.
    Hill SE; Donegan RK; Lieberman RL
    J Mol Biol; 2014 Feb; 426(4):921-35. PubMed ID: 24333014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for misfolding in myocilin-associated glaucoma.
    Donegan RK; Hill SE; Freeman DM; Nguyen E; Orwig SD; Turnage KC; Lieberman RL
    Hum Mol Genet; 2015 Apr; 24(8):2111-24. PubMed ID: 25524706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Misfolding Properties of Glaucoma-Associated Olfactomedin Domains from Humans and Mice.
    Patterson-Orazem AC; Hill SE; Wang Y; Dominic IM; Hall CK; Lieberman RL
    Biochemistry; 2019 Apr; 58(13):1718-1727. PubMed ID: 30802039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones.
    Burns JN; Orwig SD; Harris JL; Watkins JD; Vollrath D; Lieberman RL
    ACS Chem Biol; 2010 May; 5(5):477-87. PubMed ID: 20334347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Details of Olfactomedin Domains Provide Pathway to Structure-Function Studies.
    Hill SE; Donegan RK; Nguyen E; Desai TM; Lieberman RL
    PLoS One; 2015; 10(6):e0130888. PubMed ID: 26121352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligands for glaucoma-associated myocilin discovered by a generic binding assay.
    Orwig SD; Chi PV; Du Y; Hill SE; Cavitt MA; Suntharalingam A; Turnage KC; Dickey CA; France S; Fu H; Lieberman RL
    ACS Chem Biol; 2014 Feb; 9(2):517-25. PubMed ID: 24279319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion.
    Gobeil S; Letartre L; Raymond V
    Exp Eye Res; 2006 Jun; 82(6):1017-29. PubMed ID: 16466712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.
    Orwig SD; Perry CW; Kim LY; Turnage KC; Zhang R; Vollrath D; Schmidt-Krey I; Lieberman RL
    J Mol Biol; 2012 Aug; 421(2-3):242-55. PubMed ID: 22197377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Insights into Myocilin and Its Glaucoma-Causing Misfolded Olfactomedin Domain Variants.
    Lieberman RL; Ma MT
    Acc Chem Res; 2021 May; 54(9):2205-2215. PubMed ID: 33847483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation.
    Huard DJE; Jonke AP; Torres MP; Lieberman RL
    Sci Rep; 2019 Sep; 9(1):12769. PubMed ID: 31484937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and characterization of the olfactomedin domain of human myocilin.
    Nagy I; Trexler M; Patthy L
    Biochem Biophys Res Commun; 2003 Mar; 302(3):554-61. PubMed ID: 12615070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations.
    Hill SE; Kwon MS; Martin MD; Suntharalingam A; Hazel A; Dickey CA; Gumbart JC; Lieberman RL
    J Biol Chem; 2019 Aug; 294(34):12717-12728. PubMed ID: 31270212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-ligand variants of the myocilin olfactomedin propeller selected from invertebrate phyla reveal cross-talk with N-terminal blade and surface helices.
    Hill SE; Cho H; Raut P; Lieberman RL
    Acta Crystallogr D Struct Biol; 2019 Sep; 75(Pt 9):817-824. PubMed ID: 31478904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.
    Donegan RK; Lieberman RL
    Future Med Chem; 2012 Nov; 4(17):2131-4. PubMed ID: 23190098
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative differentiation of benign and misfolded glaucoma-causing myocilin variants on the basis of protein thermal stability.
    Scelsi HF; Hill KR; Barlow BM; Martin MD; Lieberman RL
    Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36579626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of genetic and structural understanding of the role of myocilin in primary open angle glaucoma.
    Kanagavalli J; Pandaranayaka E; Krishnadas SR; Krishnaswamy S; Sundaresan P
    Indian J Ophthalmol; 2004 Dec; 52(4):271-80. PubMed ID: 15693317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma.
    Caballero M; Borrás T
    Biochem Biophys Res Commun; 2001 Apr; 282(3):662-70. PubMed ID: 11401512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.